Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

LexaGene Holdings Inc. buy Subdi

Startpreis
0,92 €
11.02.21 / 50%
Kursziel
2,00 €
11.02.22
Rendite (%)
-52,92 %
Endpreis
0,44 €
20.04.21
Zusammenfassung
Diese Einschätzung wurde am 20.04.21 mit einem Endkurs von 0,44 € beendet. Herbe Verluste von -52,92 % verzeichnete die BUY Einschätzung von Subdi. Subdi hat 50% Zuversicht bei dieser Einschätzung
Rendite ohne Dividenden (%)
Name 1W 1M 1J 3J
LexaGene Holdings Inc. - - - -
iShares Core DAX® -1,35 % 3,58 % 14,23 % 18,36 %
iShares Nasdaq 100 1,17 % 7,02 % 35,39 % 58,85 %
iShares Nikkei 225® -0,33 % -0,67 % 8,62 % 6,72 %
iShares S&P 500 0,51 % 4,45 % 28,02 % 49,41 %

Kommentare von Subdi zu dieser Einschätzung

In der Diskussion LexaGene Holdings Inc. diskutieren
Einschätzung Buy
Rendite (%) -52,92 %
Kursziel 2,00
Veränderung
Endet am


Is LexaGene The Perfect Stock?


Feb. 5, 2021 11:54 AM ET  |  111 comments   |  About: Lexagene Hldgs Inc. (LXXGF), Includes: BGNE, EFLVF, GNMK

Summary

  • LexaGene has just started sales of a revolutionary automated PCR machine that can test for 27 pathogens at once in about one hour.
  • It parallels Electrovaya, which have a recent 15 bagger on, a value nanocap stock in a highly favored sector that is likely to go profitable and have extreme growth.
  • I can find nothing wrong with the company as the management, market, technology and execution are all excellent.Timing is perfect, they have just started sales with a $billion+ sales potential product and FDA approval to enter the POC market is possible in May. ...

Artikel von Darp Research ohne Paywall:

@sharewise  Die Aktie hat ihren Namen geändert:


  • 16 Oct, 2016 | 20:59


Wolfeye Resource completes reverse takeover, exits mining
LexaGene Holdings Inc., formerly Wolfeye Resource Corp., said Oct. 14 that it completed its previously announced reverse takeover transaction in which it acquired Bionomics Diagnostics Inc.

Following the deal, the company issued 20 million common shares at a deemed price of 25 Canadian cents per share in exchange for all issued and outstanding securities of Bionomics Diagnostics.

Additionally, the company changed its name to LexaGene Holdings, effective Oct. 12. LexaGene shares will begin trading on the TSX Venture Exchange as a tier 2 technology issuer under the symbol LXG.

Wolfeye will exit mining operations and will be known as a startup biotechnology company due to the move.

https://www.spglobal.com/marketintelligence/en/news-insights/blog/industry-top-trends-2021-metals-and-mining

Einschätzung Buy
Rendite (%) -52,92 %
Kursziel 2,00
Veränderung
Endet am 11.02.22

Nachkaufen?